NuSep licences gels

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.

The third party had offered to acquire NuSep's gels business outright or to license the technology.

It was decided that licensing the technology would provide the best return for shareholders, the company said.

The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.

NuSep also supplies research grade biological products such as human IgG and albumin.

Related News

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd